Drug Candidate

News

Related Video News

No related video news stories found.

Organic Broadcast Project

Related Videos

No related videos found.

Movers roundup: Williams-Sonoma, Medicis Pharma

Published December 2, 2008, 11:54 am, INO News

NEW YORK (AP) _ Shares of Williams-Sonoma Inc., which sells high-end kitchenware and home decor, jumped more than 21 percent on Tuesday after a Cowen and Co. analyst said the shares are a value at their current price but risks still loom as discounters gain market share.

Discover News | Full Story


Asthma drug from Theravance meets midstage goal

Published December 2, 2008, 11:39 am, INO News

(AP:SOUTH SAN FRANCISCO, Calif.) Biotechnology company Theravance Inc. said Tuesday its developing asthma drug improved lung function in a midstage study.

Discover News | Full Story


Anadys shares rise on review for hepatitis C drug

Published December 2, 2008, 9:55 am, INO News

(AP:NEW YORK) Shares of Anadys Pharmaceuticals Inc. rose Tuesday after the biotechnology company said the Food and Drug Administration will give its developing chronic hepatitis C drug a fast-track review.

Discover News | Full Story


Lawmakers to make picks for top Maine offices

Published December 2, 2008, 9:52 am, Bangor Daily News

AUGUSTA, Maine — The three-way race for one of the state’s most prominent public offices, attorney general, will be decided Tuesday as the newly elected Legislature chooses a nominee to head the $30 million department that represents the state in legal matters.

Discover News | Full Story


U.S FDA Grants Pralatrexate Orphan Drug Designation For The Treatment Of Patients With Follicular Lymphoma

Published December 2, 2008, 9:13 am, Medical News Today

Allos Therapeutics, Inc. (Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to the Company's novel antifolate, pralatrexate (PDX), for the treatment of patients with follicular lymphoma.

Discover News | Full Story


Patient Enrolment Completed in Phase II Clinical Trial for Allon's AL-108

Published December 2, 2008, 8:59 am, T-Net British Columbia

Vancouver, BC, December 2, 2008--(T-Net)--Allon Therapeutics Inc. (TSX:NPC) announced today that patient enrolment is complete in a Phase II clinical trial evaluating the safety and efficacy of the Company's proprietary drug candidate AL-108 in patients with schizophrenia-related cognitive impairment.

Discover News | Full Story


Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints

Published December 2, 2008, 8:27 am, EurekAlert!

( WeissComm Partners ) Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints. HZT 501, a novel, proprietary fixed-dose combination product containing ibuprofen and famotidine, demonstrated a statistically significant reduction in the ...

Discover News | Full Story


A Pragmatic Pair To Confront Terror Threat

Published December 2, 2008, 8:00 am, CBS News

In nominating Eric H. Holder Jr. and Janet Napolitano, Barack Obama selected two Dems with sterling law-and-order credentials but less experience in detecting threats and gathering intelligence in the age of terrorism, reports the Washington Post.

Discover News | Full Story


XenoPort shares dive on disappointing study

Published December 2, 2008, 7:39 am, INO News

(AP:NEW YORK) Shares of XenoPort Inc. plunged Tuesday after the biotechnology company said its heartburn drug candidate failed to improve severe heartburn symptoms in a midstage study.

Discover News | Full Story


Protalix BioTherapeutics Announces Completion of Enrollment for its Pivotal Phase III Clinical Trial of Gaucher Disease

Published December 2, 2008, 6:17 am, Centre Daily Times

Protalix BioTherapeutics, Inc. (Amex: PLX), announced today that it has completed enrollment in the Company’s pivotal phase III clinical trial of prGCD, a proprietary plant cell expressed recombinant form of human glucocerebrosidase (GCD) for the treatment of Gaucher disease. Gaucher disease is a rare and serious lysosomal storage disorder in humans.

Discover News | Full Story



News Directory

Get started fast by using a pre-defined news directory category

Breaking News
and Top Stories
Business
Earnings, Economy, Personal Finance, and Stock Markets
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss
Politics
Congress, Supreme Court, and White House
Science
Animals, Astronomy, Biotechnology, Space, and Weather
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis
Technology
Communications, Hardware, Internet, Personal Technology, and Software
United States
and Crimes and Trials
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East


© Copyright 2005-2006 News Meme, All Rights Reserved | More News | Link Index | OSWD Design

Powered by Odin Assemble 2.5a